| |
| |
|
| Insider
Information: |
Berger Franklin M |
| Relationship: |
Director |
| City: |
Brisbane |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
11 |
|
| Direct
Shares |
3,047,973 |
|
|
Indirect Shares
|
40,000 |
|
|
| Direct
Value |
$47,751,380 |
|
|
|
Indirect Value
|
$22,680 |
|
|
| Total
Shares |
3,087,973 |
|
|
| Total
Value |
$47,774,060 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
4
|
0
|
|
Stock
price went up :
|
2
|
0
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -1.7%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Seagen Inc |
SGEN |
Director |
2014-02-21 |
204,720 |
|
0 |
Premium* |
|
|
Lineage Cell Therapeutics Ord Shs |
LCTX |
Director |
2013-08-20 |
500 |
2013-08-20 |
0 |
Premium* |
|
|
Immune Design Corp. |
IMDZ |
Director |
2019-04-02 |
0 |
2014-07-29 |
0 |
Premium* |
|
|
Five Prime Therapeutics Inc |
FPRX |
Director |
2021-04-16 |
0 |
2014-11-28 |
0 |
Premium* |
|
|
Kineta Ord Shs |
KA |
Director |
2018-10-26 |
266,162 |
2018-10-26 |
40,000 |
Premium* |
|
|
Forte Biosciences Inc |
FBRX |
Director |
2017-04-19 |
25,335 |
2017-04-19 |
0 |
Premium* |
|
|
Kezar Life Sciences, Inc. |
KZR |
Director |
2022-03-21 |
890,691 |
2018-06-25 |
0 |
Premium* |
|
|
Atreca Inc |
BCEL |
Director |
2019-06-24 |
97,808 |
|
0 |
Premium* |
|
|
ESSA Pharma Inc |
EPIX |
|
2023-11-21 |
784,404 |
|
0 |
Premium* |
|
|
Atea Pharmaceuticals, Inc. |
AVIR |
Director |
2022-11-14 |
778,353 |
|
0 |
Premium* |
|
|
Rain Therapeutics Inc. |
RAIN |
Director |
2024-01-26 |
0 |
2021-04-23 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
83 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SGEN |
Seagen Inc |
Director |
– • – |
2004-07-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,000 |
|
- |
|
| BCEL |
Atreca Inc |
Director |
– • – |
2019-06-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,493 |
|
- |
|
| EPIX |
ESSA Pharma Inc |
Director |
– • – |
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
858,037 |
|
- |
|
| AVIR |
Atea Pharmaceuticals, Inc... |
Director |
– • – |
2020-10-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
18,747 |
|
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2013-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
187,220 |
0 |
- |
|
| KA |
Kineta Ord Shs |
Director |
– • – |
2016-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
71,932 |
71,932 |
0 |
- |
|
| KZR |
Kezar Life Sciences, Inc. |
Director |
– • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
459,983 |
513,157 |
0 |
- |
|
| BCEL |
Atreca Inc |
Director |
– • – |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
75,315 |
97,808 |
0 |
- |
|
| AVIR |
Atea Pharmaceuticals, Inc... |
Director |
– • – |
2020-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
759,606 |
778,353 |
0 |
- |
|
| RAIN |
Rain Therapeutics Inc. |
Director |
– • – |
2021-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
711,540 |
836,540 |
0 |
- |
|
| RAIN |
Rain Therapeutics Inc. |
Director |
– • – |
2024-01-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,005,207) |
0 |
0 |
- |
|
| EPIX |
ESSA Pharma Inc |
Director |
– • – |
2022-12-21 |
4 |
S |
$2.41 |
$174,401 |
D/D |
(72,223) |
684,404 |
0 |
- |
|
| EPIX |
ESSA Pharma Inc |
Director |
– • – |
2022-12-20 |
4 |
S |
$2.53 |
$110,351 |
D/D |
(43,617) |
756,627 |
0 |
- |
|
| KZR |
Kezar Life Sciences, Inc. |
Director |
– • – |
2020-02-04 |
4 |
B |
$2.60 |
$314,200 |
D/D |
120,846 |
684,003 |
2.39 |
% |
|
| EPIX |
ESSA Pharma Inc |
Director |
– • – |
2022-12-16 |
4 |
S |
$2.67 |
$133,500 |
D/D |
(50,000) |
800,244 |
0 |
- |
|
| EPIX |
ESSA Pharma Inc |
Director |
– • – |
2022-12-15 |
4 |
S |
$2.86 |
$235,800 |
D/D |
(82,000) |
850,244 |
0 |
- |
|
| EPIX |
ESSA Pharma Inc |
Director |
– • – |
2022-12-14 |
4 |
S |
$3.00 |
$75,000 |
D/D |
(25,000) |
932,244 |
0 |
- |
|
| EPIX |
ESSA Pharma Inc |
Director |
– • – |
2020-12-03 |
4 |
OE |
$3.23 |
$153,701 |
D/D |
42,207 |
900,244 |
0 |
- |
|
| LCTX |
Lineage Cell Therapeutics... |
Director |
– • – |
2013-08-20 |
4 |
B |
$3.71 |
$1,855 |
D/D |
500 |
500 |
2.31 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
Director |
– • – |
2019-12-02 |
4 |
S |
$3.92 |
$125,793 |
D/D |
(32,090) |
52,890 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
Director |
– • – |
2019-12-03 |
4 |
S |
$4.00 |
$191,560 |
D/D |
(47,890) |
5,000 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2006-08-15 |
4 |
A |
$4.18 |
$41,977 |
D/D |
10,000 |
71,692 |
|
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2009-07-29 |
4 |
OE |
$4.18 |
$20,900 |
D/D |
5,000 |
77,220 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • – |
2009-10-07 |
4 |
OE |
$4.18 |
$20,900 |
D/D |
5,000 |
82,220 |
0 |
- |
|
| IMDZ |
Immune Design Corp. |
Director |
– • – |
2017-10-25 |
4 |
B |
$4.26 |
$106,620 |
D/D |
25,000 |
50,000 |
2.39 |
- |
|
83 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
